The FDA declined approval for odronextamab, a drug that was already approved in Europe.
1 report, 1 independent
Updated Aug 29
AI-generated analysis. Brind wrote this summary from the reports listed below. It can be wrong. Each section says how much you can rely on it, and the sources are linked so you can check.
What happened
The FDA declined approval for odronextamab, a drug that was already approved in Europe.
Who's involved
What this event is mainly aboutKeep exploring
The entities involved
- FDA
-
Regeneron Pharmaceuticals
American pharmaceutical company
Related events
- The FDA is reviewing a drug approval application for a condition involving the company GAD.
- Amylyx Pharmaceuticals is seeking FDA approval for a new drug treatment.
- OS Therapies, Inc. is seeking interim and final review data submissions from regulatory bodies while attending major global investment conferences.
- Both the FDA and the European Medicines Agency govern drug approval processes.
- The FDA and European Medicines Agency are harmonizing regulatory review of drug applications.
Coverage
Newest first; wire copies grouped- Insider MonkeyRegeneron Pharmaceuticals, Inc. (REGN) Confident on Odronextamab Approval After Setbacks We recently compiled a list of the 11 Cheap Biotech Stocks to Buy According to Hedge Funds. Regeneron Pharmace